• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

    2/14/24 4:17:59 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email
    SC 13G/A 1 tm245885d2_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Nyxoah SA

    (Name of Issuer)

     

    Ordinary Shares

    (Title of Class of Securities)

     

    B6S7WD106

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨    Rule 13d-1(b)

    ¨    Rule 13d-1(c)

    x   Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. B6S7WD106 13G Page 2 of 5

     

    1.  

    Names of Reporting Persons

     

    TOGETHER Partnership

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3.   SEC Use Only
    4.  

    Citizenship or Place of Organization

     

    Belgium

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

      5.  

    Sole Voting Power

    2,948,285

      6.  

    Shared Voting Power

    0

      7.  

    Sole Dispositive Power

    2,948,285

      8.  

    Shared Dispositive Power

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,948,285

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ¨

    11.  

    Percent of Class Represented by Amount in Row (9)

    10.3% (1)

    12.  

    Type of Reporting Person (See Instructions)

    PN

     

     (1)   Based on 28,673,985 ordinary shares (“Ordinary Shares”) of Nyxoah S.A. (the “Issuer”) stated to be outstanding in the Issuer's Form 6-K furnished to the Securities and Exchange Commission (“SEC”) on December 11, 2023.

     

     

     

     

    CUSIP No. B6S7WD106 13G Page 3 of 5

     

    Item 1.

    (a) Name of issuer

    Nyxoah SA (the “Issuer”).

    (b) Address of issuer’s principal executive offices

    Rue Edouard Belin 12,
    1435 Mont-Saint-Guibert, Belgium

     

    Item 2.

    (a) Name of person filing

    This Schedule 13G/A is being filed by TOGETHER Partnership (the “Reporting Person”).

    (b) Address or principal business office or, if none, residence

    The principal business office of the Reporting Person is c/o Nyxoah SA, Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium.

    (c) Citizenship

    The Reporting Person is organized under the laws of Belgium.

    (d) Title of class of securities

    This Statement refers to the Ordinary Shares of the Issuer.

    (e) CUSIP No.

    The CUSIP number of the ordinary shares is B6S7WD106.

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
        (a)   ¨    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c).
        (b)   ¨   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
        (c)   ¨   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
        (d)   ¨   Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8).
        (e)   ¨    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
        (f)   ¨    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(ii)(F).
        (g)   ¨    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
        (h)   ¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
        (i)   ¨    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
        (j)   ¨    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
        (k)   ¨    Group in accordance with § 240.13d-1(b)(ii)(J).

     

     

     

     

    CUSIP No. B6S7WD106 13G Page 4 of 5

     

        If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.   Ownership

    The responses to Items 5-11 of the cover page of this Schedule 13G are incorporated herein by reference.

     

    (a) Amount beneficially owned: 2,948,285 Ordinary Shares
    (b) Percent of class: 10.3%*
    (c) Number of shares as to which the person has:
      (i) Sole power to vote or to direct the vote: 2,948,285
      (ii) Shared power to vote or to direct the vote: 0
      (iii) Sole power to dispose of or to direct the disposition of: 2,948,285
      (iv) Shared power to dispose of or to direct the disposition of: 0

     

    * Based on 28,673,985 ordinary shares (“Ordinary Shares”) of Nyxoah S.A. (the “Issuer”) stated to be outstanding in the Issuer's Form 6-K furnished to the Securities and Exchange Commission (“SEC”) on December 11, 2023.

     

    Item 5.   Ownership of 5 Percent or Less of a Class.

    Not applicable.

     

    Item 6.   Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.   Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.   Notice of Dissolution of Group.

    Not applicable.

     

    Item 10. Certifications.

    Not applicable.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

      TOGETHER Partnership
       
      By: /s/Anneliese Monden
      Name: Anneliese Monden
      Title: Authorized Signatory

     

     

     

    Get the next $NYXH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings

    $NYXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Information on the total number of voting rights and shares

      REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 29, 2025, 10:45 pm CET / 4:45 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,432,066.28 Total number of securities carrying voting rights: 37,441,140 (all ordinary shares) Total number of voting rights (= denominator): 37,441,140 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 2,793,941 (all granted subscription rig

      7/29/25 4:45:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025

      Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyx

      7/29/25 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah's DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

      Nyxoah's DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that data from its DREAM pivotal study was published online in the Journal of Clinical Sleep Medicine. The DREAM pivotal study presents comprehensive 12-month safety and efficacy results that supported the Company's PMA submission to the FDA. The peer-reviewed publication provides detailed analysis of the Genio® system's performance acros

      7/28/25 4:05:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    SEC Filings

    See more
    • SEC Form 6-K filed by Nyxoah SA

      6-K - Nyxoah SA (0001857190) (Filer)

      7/29/25 6:13:51 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Nyxoah SA

      6-K - Nyxoah SA (0001857190) (Filer)

      6/27/25 4:30:08 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Nyxoah SA

      6-K - Nyxoah SA (0001857190) (Filer)

      5/30/25 5:00:33 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Nyxoah S.A.

      H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy

      7/31/23 8:05:01 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Nyxoah S.A.

      Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral

      7/19/23 7:19:37 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Nyxoah S.A. with a new price target

      Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00

      4/21/22 7:16:59 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Financials

    Live finance-specific insights

    See more
    • Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025

      Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyx

      7/29/25 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Reports First Quarter Financial and Operating Results

      REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the first quarter of 2025. Recent Financial and Operating Highlights Received an FDA Approvable Letter indicating the FDA wil

      5/14/25 1:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025

      Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's

      5/7/25 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NYXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13D/A filed by Nyxoah SA

      SC 13D/A - Nyxoah SA (0001857190) (Subject)

      10/10/24 4:00:17 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Nyxoah SA (Amendment)

      SC 13D/A - Nyxoah SA (0001857190) (Subject)

      5/30/24 5:20:40 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

      SC 13G/A - Nyxoah SA (0001857190) (Subject)

      2/14/24 4:17:59 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Appoints John Landry as Chief Financial Officer

      Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry

      11/4/24 4:45:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Appoints Scott Holstine as Chief Commercial Officer

      Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by

      7/15/24 2:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Strengthens its Executive Leadership Team

      Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device

      11/28/23 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care